TED Ted Baker Plc

RNS Number:2575A
Tepnel Life Sciences PLC
16 July 2007


        Tepnel Life Sciences plc Extends Licence Agreement with Luminex

Manchester, UK, 16 July 2007: Tepnel Life Sciences PLC (AIM: TED), the
international Molecular Diagnostics and Research Products & Services group,
announces it has agreed to an extension of the licence with Luminex Corporation
(NASDAQ: LMNX) for access to the Luminex(R) xMAP(R) platform. The Luminex xMAP
technology is incorporated into Tepnel's innovative molecular diagnostics
products.

Tepnel's LifeMatch products are used for the measurement and detection of HLA
(Human Leukocyte Antigen) markers which are used in both bone marrow and solid
organ transplantation.  These products allow the rapid analysis of a donor's HLA
type to determine if they are a potential match for the patient waiting for a
bone marrow transplantation or a patient on a solid organ waiting list.

Tepnel develops highly multiplexed DNA and protein based assays and user
friendly software for its highly successful LifeMatch product line.  The Luminex
technology allows Tepnel Lifecodes' customers to analyze up to 100 simultaneous
reactions on a single patient's sample in a user friendly, cost effective manner
with minimal hands-on time.

Tepnel's CEO Ben Matzilevich commented "We are pleased to extend our agreement
for the use of Luminex's xMAP technology for our Molecular Diagnostics Division.
The xMAP technology provides a powerful platform when combined with our
state-of-the-art LifeMatch family of Lifecodes assays and software.  We continue
to extend our leadership position in the field of organ transplantation and
anticipate strong continued growth for the LifeMatch product lines."

Luminex Corporation President and CEO Patrick Balthrop stated, "Customers in the
HLA market have led the way toward improving efficiency of diagnostic testing
through multiplexing.  HLA customers have rapidly converted standard
protein-based ELISA tests to multiplexed tests based on xMAP technology.
Additionally, these same customers take advantage of the flexibility of xMAP
technology by also testing nucleic acids, where up to 100 different markers per
sample are analyzed routinely.   We are pleased to continue working with Tepnel
to deliver multiplexed solutions in the HLA market and continue to be
enthusiastic about xMAP's ability to satisfy the increasing performance demands
of our partners and customers."

Tepnel's LifeMatch product line is rapidly gaining market share in the USA,
Europe and ROW.  In January of this year, Tepnel extended the LifeMatch product
lines with two new product offerings, LSA(TM) and DSA(TM).  LSA is a highly
multiplexed assay system consisting of more than 150 cloned recombinant
proteins.  This assay allows clinicians to accurately identify permissible
allele level antigens in highly sensitized patients in order to minimize the
chance of rejection and ensure a better outcome.  The DSA product line allows
clinicians to screen the patient for the presence of antibodies against HLA
antigens of the donor ensuring compatibility and minimizing rejection.  Tepnel
will continue to expand its Lifecodes product lines in order to meet the needs
of the transplant community.

                                     -Ends-

For Further Information:

Tepnel Life Sciences plc
Ben Matzilevich, CEO
Carol Smith
Tel: 0161 946 2200

Capital MS&L
Mary Clark or Catie Corcoran
Tel: +44 20 7307 5330
Email: mary.clark@capitalmsl.com


Notes to Editors

About Tepnel Life Sciences plc

Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences
products and services group with two divisions, Molecular Diagnostics and
Research Products & Services. The Company has laboratories, manufacturing and
operations in the USA, UK and France with 195 employees.  TLS provides test
kits, reagents and services to two highly synergistic markets, these being
Molecular Diagnostics and Biomedical Research.  The company's strategy has been
to identify high growth niche opportunities within these multi-billion pound
markets.  TLS focuses on these niche opportunities with internally developed
products, patents, expertise and know-how as well as strategic acquisitions, to
develop a leadership position within these defined market segments.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGRDXLFFDDBBBBL

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024